Baseline characteristics in AML patients receiving FM, FB RIC regimen for allogeneic HCT (full cohort)
| . | FM . | FB . | P . |
|---|---|---|---|
| Patient-related | |||
| No. of patients | 622 | 791 | |
| No. of centers | 73 | 80 | |
| Age at transplant, y | |||
| Median (range) | 59 (18-76) | 61 (18-77) | <.001 |
| Male sex, n (%) | 359 (58) | 445 (56) | .58 |
| Karnofsky score, n (%) | .19 | ||
| <90 | 290 (47) | 336 (43) | |
| ≥90 | 311 (50) | 416 (52) | |
| Disease status before HCT, n (%) | |||
| Primary induction failure | 120 (19) | 86 (11) | <.001 |
| CR1 | 285 (46) | 484 (62) | |
| ≥CR2+ | 110 (18) | 163 (20) | |
| Relapse | 106 (17) | 57 (7) | |
| MRD status before transplant | <.001 | ||
| Negative | 127 (20) | 257 (33) | |
| Positive | 40 (6) | 63 (8) | |
| Not in CR1 | 138 (22) | 190 (24) | |
| NA before 2007 | 310 (50) | 244 (31) | |
| Cytogenetic score | .96 | ||
| Favorable | 36 (6) | 50 (6) | |
| Intermediate | 323 (52) | 425 (54) | |
| Poor | 200 (32) | 266 (34) | |
| Therapy-related/secondary AML | .56 | ||
| No | 533 (86) | 689 (87) | |
| Yes | 75 (12) | 88 (11) | |
| Transplant-related, n (%) | |||
| Donor type | <.001 | ||
| HLA-identical sibling | 130 (21) | 241 (30) | |
| Well-matched unrelated (8/8) | 335 (54) | 427 (54) | |
| Partially-matched unrelated (7/8) | 115 (18) | 95 (12) | |
| Mismatched unrelated (≤6/8) | 18 (3) | 5 (< 1) | |
| Donor age at HCT (for URD only) | .006 | ||
| Median (range) | 38 (16-85) | 39 (11-82) | |
| GVHD prophylaxis | <.001 | ||
| TAC-based + MTX | 238 (38) | 493 (63) | |
| TAC-based + MMF | 132 (21) | 158 (20) | |
| CsA-based + MTX | 49 (8) | 18 (2) | |
| CsA-based + MMF | 70 (11) | 32 (4) | |
| ATG/alemtuzumab use | 259 (42) | 413 (52) | <.001 |
| Graft type | <.001 | ||
| Bone marrow | 119 (19) | 73 (9) | |
| Peripheral blood | 503 (81) | 726 (91) | |
| Year of transplant | <.001 | ||
| 2001-2005 | 180 (29) | 98 (12) | |
| 2006-2015 | 442 (71) | 693 (88) | |
| Median follow-up (range), mo | 85 (6-168) | 72 (6-169) |
| . | FM . | FB . | P . |
|---|---|---|---|
| Patient-related | |||
| No. of patients | 622 | 791 | |
| No. of centers | 73 | 80 | |
| Age at transplant, y | |||
| Median (range) | 59 (18-76) | 61 (18-77) | <.001 |
| Male sex, n (%) | 359 (58) | 445 (56) | .58 |
| Karnofsky score, n (%) | .19 | ||
| <90 | 290 (47) | 336 (43) | |
| ≥90 | 311 (50) | 416 (52) | |
| Disease status before HCT, n (%) | |||
| Primary induction failure | 120 (19) | 86 (11) | <.001 |
| CR1 | 285 (46) | 484 (62) | |
| ≥CR2+ | 110 (18) | 163 (20) | |
| Relapse | 106 (17) | 57 (7) | |
| MRD status before transplant | <.001 | ||
| Negative | 127 (20) | 257 (33) | |
| Positive | 40 (6) | 63 (8) | |
| Not in CR1 | 138 (22) | 190 (24) | |
| NA before 2007 | 310 (50) | 244 (31) | |
| Cytogenetic score | .96 | ||
| Favorable | 36 (6) | 50 (6) | |
| Intermediate | 323 (52) | 425 (54) | |
| Poor | 200 (32) | 266 (34) | |
| Therapy-related/secondary AML | .56 | ||
| No | 533 (86) | 689 (87) | |
| Yes | 75 (12) | 88 (11) | |
| Transplant-related, n (%) | |||
| Donor type | <.001 | ||
| HLA-identical sibling | 130 (21) | 241 (30) | |
| Well-matched unrelated (8/8) | 335 (54) | 427 (54) | |
| Partially-matched unrelated (7/8) | 115 (18) | 95 (12) | |
| Mismatched unrelated (≤6/8) | 18 (3) | 5 (< 1) | |
| Donor age at HCT (for URD only) | .006 | ||
| Median (range) | 38 (16-85) | 39 (11-82) | |
| GVHD prophylaxis | <.001 | ||
| TAC-based + MTX | 238 (38) | 493 (63) | |
| TAC-based + MMF | 132 (21) | 158 (20) | |
| CsA-based + MTX | 49 (8) | 18 (2) | |
| CsA-based + MMF | 70 (11) | 32 (4) | |
| ATG/alemtuzumab use | 259 (42) | 413 (52) | <.001 |
| Graft type | <.001 | ||
| Bone marrow | 119 (19) | 73 (9) | |
| Peripheral blood | 503 (81) | 726 (91) | |
| Year of transplant | <.001 | ||
| 2001-2005 | 180 (29) | 98 (12) | |
| 2006-2015 | 442 (71) | 693 (88) | |
| Median follow-up (range), mo | 85 (6-168) | 72 (6-169) |